Target
A target enters the platform when we have a structure, a measurable engagement assay, and a human-genetics rationale. Targets without all three wait.
Platform
A structure-guided discovery platform, measured in months.
Every program in our pipeline starts with a high-resolution structure and a measurable engagement assay. The platform below is the discipline that turns a structure into a candidate in a median of 24 months.
Approach
Structure first, then chemistry.
We do not run discovery campaigns without a structure. The structure tells us where the molecule has to go, the assay tells us whether it got there, and the selectivity panel tells us whether it went only there.
Hit
Fragment screening and computational chemistry produce starting matter. We require a co-crystal structure for every hit before it advances.
Lead
Medicinal chemistry iterates against a written candidate criteria sheet covering potency, selectivity, ADME, and in vivo pharmacology.
Candidate
A candidate is nominated when GLP toxicology, CMC and clinical supply plans are in place. From structure to candidate across our last three programs: 24 months median.
Mechanism library
How each program works, in motion.
Each mechanism of action is shown as a self-contained SVG animation. Pause controls are visible; the animation pauses when scrolled out of view and respects reduced-motion preference.
Cyclin-dependent kinase 4/6 (CDK4/6)
BPC-101 binds the ATP pocket of CDK4 and CDK6 with high selectivity over CDK1 and CDK2, halting RB phosphorylation and arresting the cell cycle in G1.
Read program brief Cluster of differentiation 19 (CD19)
BPC-203 binds CD19 on the surface of B cells and recruits natural killer cells through its engineered Fc, driving selective depletion of malignant B cells.
Read program brief Tyrosine kinase 2 (TYK2)
BPC-305 tags TYK2 for proteasomal degradation via a molecular glue, removing the signaling scaffold required for interferon-alpha receptor signal transduction.
Read program briefCapabilities
What the platform can do today.
Modalities
- Small molecules (oral)
- Monoclonal antibodies
- Antibody-drug conjugates
- Gene therapy (AAV)
Disease areas
- Oncology — solid tumor and hematologic
- Immunology — IBD and autoimmune
- Rare disease — inherited metabolic
Internal capability
- Structure biology (X-ray, cryo-EM)
- Medicinal and process chemistry
- Biomarker and translational research
- Clinical operations across two continents
Open data
- Program tracker — internal, summary published
- Publication library — peer-reviewed
- Trial registry — linked from trials page
6Programs in development
2Research sites
8Peer-reviewed publications
24Median months, structure to candidate (sample)